MET activation may compensate for EGFR pathway inhibition via activation of the downstream PI3K pathway, and may correlate with acquired resistance to EGFR TKIs in patients with EGFR-mutant NSCLC [47]. The gene discussed is MET; the disease is non-small cell lung carcinoma.